Connect With UsI'm a Patient
Narcolepsy Link logo
Narcolepsy Link logo
  • About Narcolepsy
    • Pathophysiology
  • Screening & Diagnosis
    • Identifying Narcolepsy
    • Screeners
    • Diagnostic Criteria
    • Diagnostic Process
    • Diagnostic Challenges
  • Comorbidity Risk
    • Cardiovascular Comorbidities
    • Modifiable Risks for CV Disease
    • High Sodium Intake and CV Disease
    • Excess Sodium Intake Impact on Certain Body Systems
    • Psychiatric and Sleep Comorbidities
  • Disease Management
    • Management Considerations
  • Pediatric Patients
    • Burden of Illness
    • Symptoms
    • Clinical Interview
    • Differential Diagnosis
    • Screening
    • Patient and Caregiver Perspectives
  • Stay Connected
    • Connect With Us
    • Sleep Organizations
    • About NarcolepsyLink
  • Resources
    • Expert Clinical Insights
    • Clinical Resources
    • Narcolepsy FAQs
    • Glossary of Terms

Frequently Asked Questions About Narcolepsy

What is narcolepsy?

What are the most common comorbidities that may mask the symptoms of narcolepsy?

Has an increased prevalence of certain CV comorbidites been observed in patients with narcolepsy?

What are long-term considerations for narcolepsy management?

  1. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol. 2003;53(2):154-166.
  2. Rosenberg R, Kim AY. The AWAKEN survey: knowledge of narcolepsy among physicians and the general population. Postgrad Med. 2014;126(1):78-86.
  3. Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med. 2010;31(2):371-381.
  4. National Institute of Neurological Disorders and Stroke. Narcolepsy fact sheet. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Narcolepsy-Fact-Sheet. Accessed November 10, 2020.
  5. American Academy of Sleep Medicine. Central disorders of hypersomnolence. In: The International Classification of Sleep Disorders – Third Edition (ICSD-3) Online Version. Darien, IL: American Academy of Sleep Medicine; 2014.
  6. Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy—clinical aspects, pathophysiology and management strategy. Nat Rev Neurol. 2014:10(7):386-395.
  7. Overeem S, van Nues SJ, van der Zande WL, Donjacour CE, van Mierlo P, Lammers GJ. The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. Sleep Med. 2011;12(1):12-18.
  8. Carter LP, Acebo C, Kim A. Patients’ journeys to a narcolepsy diagnosis: a physician survey and retrospective chart review. Postgrad Med. 2014;126(3):216-224.
  9. Luca G, Haba-Rubio J, Dauvilliers Y, et al; European Narcolepsy Network. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep Res. 2013;22(5):482-495.
  10. Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014;15(5):502-507.
  11. Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013;14(6):488-492.
  12. Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. Sleep Med. 2017;33:13-18.
  13. Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39-57.
Jazz Pharmaceuticals Logo
NarcolepsyLink® is sponsored by Jazz Pharmaceuticals
©2024 Jazz Pharmaceuticals plc or its subsidiaries
US-SLE-2100121 REV0924
Connect With UsPrivacy StatementSite MapAbout NarcolepsyLink
Jazz Pharmaceuticals Logo